Can Reblozyl Power Bristol Myers' Top-Line Growth Going Forward?

Bristol Myers’ Reblozyl sales neared $1.3 billion in the first half of 2026, up 23% year over year, supporting growth as legacy-drug sales decline. The FDA accepted an application to expand Reblozyl for myelofibrosis-associated anemia, with a target action date of March 11, 2027; a separate Phase III study is expected to report data in 2028. BMY shares were up 10.5% year to date, and consensus EPS estimates rose to $6.91 for 2026 and $6.46 for 2027.

Analysis

The investment question is not whether Reblozyl is growing, but whether its incremental contribution can outrun erosion in BMY’s legacy base. A growing drug can still fail to stabilize consolidated revenue if launch ramps elsewhere disappoint or older-product declines accelerate; track growth-portfolio revenue against the legacy contraction, not Reblozyl growth in isolation. Also verify reported net sales and BMY’s retained economics on the partnered product before translating product growth into earnings power.

Competition looks more segmented than the headline framing implies. Rytelo’s current label targets a narrower, heavily transfusion-dependent second-line population, so it is not yet a clean read-through to Reblozyl’s broader first-line MDS uptake. Its expansion into myelofibrosis, and Takeda/Keros’ trial, matter more as 2027–28 threats than as immediate share losses. Reblozyl’s own myelofibrosis decision is a nearer catalyst, but approval would not by itself establish adoption, duration, or incremental net revenue.

Contrarian read: the apparent valuation discount may reflect a genuine durability/LOE and portfolio-transition risk, not simply a mispriced growth asset. The article supplies no indication-level sales, product economics, or quantified legacy decline, so a multiple rerating is not yet underwritten. Near term, expect limited fundamental repricing absent guidance changes; over 1–3 months, quarterly prescription/revenue trends and management’s bridge matter; over 6–18 months, the FDA decision and competing trial progress shape the growth runway. Thesis weakens if Reblozyl growth decelerates while legacy erosion persists, or if BMY cuts forward guidance.

Key Decisions for Investors

• BMY: favor a measured, staged long rather than chasing the reported growth; add only if subsequent results show growth-portfolio gains offsetting legacy declines. Reassess on quarterly revenue/guidance and the March 2027 FDA decision; exit or reduce if the offset fails or forward guidance is cut.
• GERN: do not short solely on presumed Reblozyl displacement. Monitor Rytelo uptake and trial progress in myelofibrosis; a short thesis needs evidence of label expansion or share capture in overlapping populations, not just current sales growth.
• KROS/TAK: treat the myelofibrosis program as a catalyst watch, not a current BMY displacement trade. Update exposure on trial data and partnership economics; the stated milestone is not evidence of commercial revenue.
• Before sizing BMY, verify Reblozyl’s net sales by indication, BMY’s partnership economics, and the size/rate of legacy-product declines. Those missing inputs determine whether the growth is enough to support consolidated earnings.